Lion TCR Awarded Singapore’s 2023 T-Up Excellence Award Amid IPO Filing

Singapore, November 2, 2023 /PRNewswire/ -- Lion TCRAt the 2023 Singapore Week of Innovation and Technology (SWITCH)Guangzhou Laien Biological Medicine Co., Ltd. was awarded the 2023 Singapore T-Up Excellence Award. Laien Bio is a clinical-stage biotechnology company incubated by the Agency for Science, Technology and Research (A*STAR) in Singapore. The awardAt the same timeAwarded to Dr. Lu'en Wei, Senior Director of R&D at Laien Bio, and Dr. Xiaofang Xu, Director of Technical Production at Laien Bio, in recognition of their outstanding contributions to the development and innovation of Laien Bio and even Singapore's biotech sector. The Technology Enterprise Capability Upgrade (T-Up) is part of A*STAR’s GET-Up (Growing Enterprises Through Technology Upgrade) program.

Award Ceremony: Singapore's Minister for Trade and Industry Gan Kim Yong (front row, third from the left), Chairman of Enterprise Singapore Peter Ong (front row, fourth from the left), CEO of A*STAR Frederick Chew (back row, second from the left), CEO of Guangzhou Laien Biological Medicine Co., Ltd. Peng Xiaoming (back row, first from the right), Senior Director of Guangzhou Laien Biological Medicine Co., Ltd. Wei Lu'en (front row, fourth from the right), Director of Guangzhou Laien Biological Medicine Co., Ltd. Xu Xiaofang (front row, third from the right).

The GET-Up initiative aims to enhance the competitiveness of technology-intensive enterprises in Singapore, equipping businesses with the skills and expertise required for a knowledge-based economy. The GET-Up initiative comprises three key programs:

Dr. Peng Xiaoming, CEO of Guangzhou Laien Biological Medicine Co., Ltd., congratulated the company on winning the 2023 Singapore T-Up Excellence Award and expressed gratitude for the outstanding contributions of Dr. Wei Luen and Dr. Xu Xiaofang.Dr. Wei Lu'en and Dr. Xu Xiaofang are also recipients of the A*STAR Scholarship, having obtained their Ph.D.s from Stanford University in the United States and Karolinska Institutet in Sweden, respectively.This award will become a catalyst for Guangzhou Laien Biological Medicine Co., Ltd. to further enhance its technology: "The T-Up program promoted by the Agency for Science, Technology and Research (A*STAR) has played a significant role in enhancing Laien Biological's R&D capabilities and advancing the progress of mRNA-based T-cell immunotherapy," said Dr. Peng. "The talent from A*STAR has made outstanding contributions in this area, not only improving Laien Biological’s R&D capabilities but also strengthening Singapore’s position as a hub for biotechnology innovation. These efforts have greatly accelerated technological innovation and R&D, leading to the creation of innovative products and related intellectual property. Additionally, they have significantly driven business expansion, improved operational efficiency, and facilitated Laien Biological's global business growth."

In October this year, Katalin Kariko and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their groundbreaking achievements in mRNA vaccine research, which laid the foundation for Moderna as well as the collaboration between Pfizer and BioNTech on vaccines. A revolutionary application of mRNA technology is its use in cancer treatment, which remains an unmet global medical need. Guangzhou Laien Biological Medicine Co., Ltd. utilizes mRNA-encoded TCR to provide solutions for cutting-edge cell therapies in liver cancer.Laien BioThe FIRST-IN-CLASS HBV-specific TCR-T cell therapy has initially demonstrated therapeutic potential as a safe and effective treatment. More promisingly, mRNA technology paves the way for "off-the-shelf" immune cell therapies. This innovative approach allows for the in vivo generation of TCR-T cells, opening possibilities for more accessible and cost-effective treatments. Outstanding talents nurtured under the T-Up program, such as Dr. Lu’en Wei and Dr. Xiaofang Xu, have played key roles in advancing the progress of Guangzhou Laien Biological Medicine Co., Ltd.'s products and have contributed to the advancement and innovation of mRNA-based T-cell immunotherapy. Their expertise and dedication have also accelerated our progress toward breakthrough cancer therapies.

The Singapore T-Up Excellence Award recognizes the valuable role played by talents trained by the Agency for Science, Technology and Research (A*STAR) in driving innovation and growth for Singapore enterprises. Guangzhou Laien Biological Medicine Co., Ltd. is honored to receive this award and looks forward to continuing its transformative work in the biotechnology industry, advancing mRNA-based T-cell immunotherapy to conquer tumors and benefit society.

Finally,Happy to share Laien BioAn article co-published with the Agency for Science, Technology and Research in Singapore. This article reveals the underlying principles behind Guangzhou Laien Biological Medicine Co., Ltd.'s revolutionary cancer therapy. For more details,CanInHereRead the details of this article.